PLYX net incomeQ2 2026-$1.38M
PLYX net income was -$1.38M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.01M a year earlier. For the full fiscal 2025 it was -$8.98M, compared with -$30.36M in fiscal 2024.
Polaryx Therapeutics Inc. (PLYX) financials
For fiscal 2025 (ended Dec 31, 2025), Polaryx Therapeutics Inc. reported -$8.98M of net income.
- Net income, FY2025
- -$8.98M
- EPS, diluted, FY2025
- -$0.20
- Cash
- $11.54M
- Market cap
- $86.7M
FY2024FY2025
PLYX revenue and earnings growth
PLYX EPSQ2 2026-$0.03
PLYX diluted EPS was -$0.03 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.02 a year earlier. For the full fiscal 2025 it was -$0.20, compared with -$0.89 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $6.27M | $2.81M |
| Selling, general and admin | $1.55M | $1.54M |
| Operating income | -$7.82M | -$4.35M |
| Pre-tax income | -$8.98M | -$30.36M |
| Net income | -$8.98M | -$30.36M |
| EPS, basic | -$0.20 | -$0.89 |
| EPS, diluted | -$0.20 | -$0.89 |
| Diluted shares | 45.4M | 34.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $5.14M | $4.62M |
| Current assets | $5.17M | $5.00M |
| Total assets | $5.17M | $5.00M |
| Current liabilities | $605.0K | $289.0K |
| Total liabilities | $605.0K | $289.0K |
| Shareholders' equity | $4.57M | $4.71M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$3.94M | -$2.57M |
| Financing cash flow | $4.47M | $7.19M |
| Stock-based compensation | $4.72M | $2.40M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Research and development | $719.0K | $679.0K | $476.0K | $4.72M |
| Selling, general and admin | $661.0K | $1.28M | $408.0K | $336.0K |
| Operating income | -$1.38M | -$1.96M | -$884.0K | -$5.05M |
| Net income | -$1.38M | -$2.54M | -$1.01M | -$5.05M |
| EPS, basic | -$0.03 | -$0.05 | -$0.02 | -$0.11 |
| EPS, diluted | -$0.03 | -$0.05 | -$0.02 | -$0.11 |
| Diluted shares | 48.3M | 47.2M | 44.7M | 44.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Cash and equivalents | $11.54M | $3.08M | - | - |
| Current assets | $11.81M | $3.50M | - | - |
| Total assets | $11.81M | $3.50M | - | - |
| Current liabilities | $873.0K | $1.01M | - | - |
| Total liabilities | $873.0K | $1.01M | - | - |
| Shareholders' equity | $10.94M | $2.49M | $3.25M | $4.25M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Operating cash flow | -$1.37M | -$2.06M | -$858.0K | -$709.0K |
| Financing cash flow | - | - | $0 | $250.0K |
| Stock-based compensation | $0 | $467.0K | $109.0K | $4.45M |
Key ratios
Source: XBRL data Polaryx Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PLYX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PLYX | - | - | -$8.98M | - | $86.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.28T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $655.56B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $509.50B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $362.53B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $308.99B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.75B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $196.57B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.45B |
PLYX FAQ
5 questionsIs PLYX profitable?
No. Polaryx Therapeutics Inc. reported a net loss of $8.98M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PLYX have?
Polaryx Therapeutics Inc. reported $11.54M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PLYX earnings per share?
Diluted earnings per share were -$0.20 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did PLYX last report financial results?
The latest statements here come from Polaryx Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this PLYX financial data come from?
Quantisnow builds these statements from the structured XBRL data Polaryx Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.